Why McKesson (MCK) is a Top Momentum Stock for the Long-Term

McKesson (MCK), a leading pharmaceutical distributor, is highlighted as a top momentum stock, earning an 'A' rating for both its Momentum and overall VGM (Value, Growth, Momentum) Style Scores, despite its Zacks Rank #3 (Hold). The company's shares have risen 8.2% over the past four weeks, supported by seven analysts who recently revised FY26 earnings estimates upwards, increasing the consensus to $37.84 per share. This positive sentiment is further bolstered by key growth drivers, including GLP-1 medications, which alone contributed nearly $41 billion in FY25 revenues.

Analysis

McKesson Corporation (MCK) is exhibiting strong momentum signals, underscored by an 8.2% share price increase over the past four weeks and a top-tier 'A' rating for its Momentum Style Score. This technical strength is fundamentally supported by positive analyst sentiment, with seven analysts revising fiscal 2026 earnings estimates upward in the last 60 days, lifting the consensus forecast by $0.58 to $37.84 per share. The company's consistent, albeit modest, history of beating expectations is evidenced by a +1.5% average earnings surprise. A key driver for this positive outlook is MCK's strategic position in high-growth areas, particularly the distribution of GLP-1 medications, which accounted for nearly $41 billion in revenue in fiscal 2025. The combination of a neutral Zacks #3 (Hold) rank with a strong 'A' for its overall VGM (Value, Growth, Momentum) score indicates that while the stock may not meet the criteria for a 'Strong Buy' based on the magnitude of estimate revisions alone, its underlying momentum and growth characteristics are highly favorable.

Key Decisions for Investors

• Given the stock's 8.2% price increase over the past four weeks and its 'A' Momentum Score, investors following momentum strategies should view the current trend as fundamentally supported by upward earnings revisions.
• Investors should scrutinize the company's valuation in light of its neutral Zacks #3 'Hold' rank, as the powerful growth narrative from its GLP-1 business, which generated nearly $41 billion in FY25 revenue, may already be reflected in the current share price.
• Closely monitor the trajectory of analyst earnings estimates for fiscal 2026, as continued upward revisions are critical to sustaining the positive momentum thesis despite the neutral overall rank.